Bryan Krumm
Psychiatric/Mental Health · Albuquerque, NMNPI 1457547796
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 34.4% of the total. 2025 is the largest year on record at $1,043, more than ten times the $66 reported in 2021.
Across 134 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$778
- AbbVie$461
- Teva Pharmaceuticals USA, Inc.$393
- Johnson & Johnson$138
- Neurocrine Biosciences, Inc.$93
- E.r. Squibb & Sons, L.L.C.$87
- plus $313 from 7 others
What the payments were for
- Food & beverage$2,263100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $778 |
| AbbVie | 26 | $461 |
| Teva Pharmaceuticals USA, Inc. | 22 | $393 |
| Johnson & Johnson | 9 | $138 |
| Neurocrine Biosciences, Inc. | 4 | $93 |
| E.r. Squibb & Sons, L.L.C. | 5 | $87 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Alkermes, Inc. | 3 | $62 |
| Jazz Pharmaceuticals Inc. | 2 | $46 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Braeburn Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $22 |
How this compares
$2,263 in reported general payments places this provider in the 85th percentile of 228 psychiatric/mental health providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 116 | $9,446 |
| Chlorpromazine Hcl | 49 | $4,846 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,695 |
| Bupropion XlBupropion Hcl | 131 | $4,681 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 139 | $4,035 |
| Prazosin Hcl | 105 | $3,636 |
| Lurasidone Hcl | 50 | $2,984 |
| Quetiapine Fumarate | 115 | $2,287 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 34 | $1,939 |
| Trazodone Hcl | 142 | $1,894 |
| Risperidone | 57 | $1,887 |
| Ziprasidone Hcl | 35 | $1,598 |
| Oxcarbazepine | 14 | $1,591 |
| Fluoxetine Hcl | 111 | $1,474 |
| Clonazepam | 159 | $1,427 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Albuquerque
- Martha SnowAlbuquerque$13K
- Tiny AdamsAlbuquerque$6K
- Rhodah SimiyuAlbuquerque$4K
- Melissa LeuzziAlbuquerque$4K
- Petra Lamla LabanAlbuquerque$3K
- Jennifer ClysdaleAlbuquerque$3K
- Diane ElmanAlbuquerque$2K
- Charlotte NkwentiAlbuquerque$2K
- Desiree ProvencioAlbuquerque$2K
- Denis MuebakeAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.